Entera Bio Ltd
Entera Bio Ltd (ENTX) Historical Volatility
ENTX's 30 day historical volatility is 67.70%, in the 20th percentile of readings over the past year. This is a low percentile, meaning Entera Bio Ltd shares have been calmer than usual. ENTX's 30 day implied volatility sits at 315.12%, with an IV Rank of 29.37%, leaving IV 247.42 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking ENTX historical volatility helps you see how much Entera Bio Ltd's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ENTX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ENTX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ENTX's 30 day historical volatility, or ENTX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ENTX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.
Historical Volatility
Historical movement is subdued versus the past year. The stock has been unusually quiet.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →